Stephen D. Gillies - Concepedia

Author

Stephen D. Gillies

Also Known As

Gillies, S.D., Monica M. Gressett, S D Gillies, S Gillies, S. D. Gillies, S. Gillies, S.D. Gillies, Stephen D Gillies, Stephen D. Gillies, Stephen Gillies

246

Publications

12.2K

Citations

H-Index

112

Concepts

All Affiliations

University of Wisconsin–Madison Scripps Research Institute scPharmaceuticals (United States)University of Wisconsin Carbone Cancer Center Harvard University

About

Stephen D. Gillies is an author at University of Wisconsin–Madison specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	67	5.7K
2	Natural Sciences	5	5	381
3	Allergy	5	5	271
4	Health Sciences	3	3	103
5	Engineering	1	1	68

Stephen D. Gillies

129

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Human Lymphoid and Myeloid Cell Development in NOD/LtSz- <i>scid IL2R</i> γ <i>null</i> Mice Engrafted with Mobilized Human Hemopoietic Stem Cells, Leonard D. Shultz, Bonnie Lyons, Lisa Burzenski, The Journal of Immunology	2005	1.7K
A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene Stephen D. Gillies, Sherie L. Morrison, Vernon T. Oi, Cell ImmunogeneticsGeneticsGene StructureGene RegulationMajor Intron	1983	1.4K
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis Karen S. Moulton, Khashayar Vakili, David Zurakowski, Proceedings of the National Academy of Sciences	2003	650
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus Adrian Hayday, Stephen D. Gillies, Haruo Saito, Nature HistocompatibilityImmunogeneticsAutoimmune DiseaseImmunologyAutoimmunity	1984	273
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study Suzanne Shusterman, Wendy B. London, Stephen D. Gillies, Journal of Clinical Oncology	2010	238
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. Barbara M. Mueller, Cynthia A. Romerdahl, Stephen D. Gillies, The Journal of Immunology Immunocytochemical TechniqueImmunologyImmunoeditingImmunotherapyGlioma	1990	184
NK cells engineered to express a GD<sub>2</sub>‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin Ruth Esser, Tina Müller, Dörthe Stefes, Journal of Cellular and Molecular Medicine Cell TherapyImmune RegulationImmunologyNk Cells-Specific Nk Cells	2011	183
A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini, Clinical Cancer Research	2006	179
Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy Holger N. Lode, Rong Xiang, Torsten Dreier, Blood	1998	178
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Stephen D. Gillies, Edward B. Reilly, Kin-Ming Lo, Proceedings of the National Academy of Sciences ImmunologyImmunologic MechanismImmunotherapeuticsImmunotherapyIl2 Activity	1992	177

Page 1